In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Brainstorm Cell Therapeutics Inc.. Trade Record

NASDAQ:BCLI Brainstorm Cell Therapeutics Inc. stock gains 27.90% Exit Jun 7, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart BCLI May 11, 2018, priceSeries
About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
76.41
Entry Date
May 11, 2018
Entry Price
3.64
Sell Date
Jun 7, 2018
Sell Price
4.66
Net Gain
27.90%
Hold Time
18 Trading Days